HomeCompareNRBT vs MRK

NRBT vs MRK: Dividend Comparison 2026

NRBT yields 10000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NRBT wins by $55137509079256512.00M in total portfolio value
10 years
NRBT
NRBT
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full NRBT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NRBT vs MRK

📍 NRBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNRBTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NRBT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NRBT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NRBT
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NRBT beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NRBT + MRK for your $10,000?

NRBT: 50%MRK: 50%
100% MRK50/50100% NRBT
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NRBT
No analyst data
Altman Z
1.7
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NRBT buys
0
MRK buys
0
No recent congressional trades found for NRBT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNRBTMRK
Forward yield10000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$55137509079256512.00M$56.8K
Annual income after 10y$54,073,795,673,722,890,000,000.00$9,798.13
Total dividends collected$55066727460582336.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NRBT vs MRK ($10,000, DRIP)

YearNRBT PortfolioNRBT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,206$366.19+$999.5KNRBT
2$95,539,393$94,457,943.93$12,650$502.35+$95.53MNRBT
3$8,447,007,736$8,344,780,585.66$14,407$694.19+$8446.99MNRBT
4$698,565,746,383$689,527,448,105.17$16,585$967.82+$698565.73MNRBT
5$54,040,711,670,213$53,293,246,321,583.74$19,342$1,363.89+$54040711.65MNRBT
6$3,910,851,616,519,516$3,853,028,055,032,387.00$22,913$1,947.19+$3910851616.50MNRBT
7$264,781,167,546,477,440$260,596,556,316,801,570.00$27,662$2,823.89+$264781167546.45MNRBT
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$34,159$4,173.35+$16772556223821.64MNRBT
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$43,337$6,308.80+$994124678068810.00MNRBT
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$56,776$9,798.13+$55137509079256512.00MNRBT

NRBT vs MRK: Complete Analysis 2026

NRBTStock

Novus Robotics Inc., through its subsidiary, D&R Technology Inc., engages in engineering, designing, manufacturing, and selling automated tube processing solutions for the automotive industry worldwide. The company designs and installs retrofits to existing automated systems, as well as offers spare parts, maintenance, and repair and production support services to automotive tier I businesses and their suppliers. Its products include seat frame systems, IP tube systems, and integrated bend-weld systems. The company also provides value added services, including system upgrades and rebuilds, control system upgrades, tooling retrofits, pre-production and prototyping requirements, training, equipment relocation and redeployment, systems audit, manufacturing consulting, and project management services. The company offers its products to automotive seating manufacturers and manufacturers of tubing products. Novus Robotics Inc. was founded in 2004 and is based in Mississauga, Canada.

Full NRBT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NRBT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NRBT vs SCHDNRBT vs JEPINRBT vs ONRBT vs KONRBT vs MAINNRBT vs JNJNRBT vs ABBVNRBT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.